Table 2.
Indicated neuroblastoma cell lines were treated with increasing doses of either ceritinib or crizotinib for 72 h and cell viability was assessed by resazurin assay
| Cell line | ALK status | MYCN status | IC50 nM (ceritinib) | IC50 nM (crizotinib) |
|---|---|---|---|---|
| CLB-GE | F1174V, A | A | 131.3 ± 24 | 233.7 ± 18 |
| CLB-BAR | g-o-f Δexon 4-12 | A | 36.1 ± 6.2 | 54.9 ± 20 |
| KELLY | F1174L, A | A | 328.9 ± 36 | 333.3 ± 78 |
| CLB-GAR | R1275Q | NA | 102.3 ± 16 | 119.3 ± 45 |
| IMR32 | wt | A | >500 | 348.7 ± 45 |
| SK-N-BE | wt, NA | A | >1500 | >1000 |
| SK-N-DZ | wt | A | >800 | >4000 |
| SK-N-AS | wt, NA | NA | >3000 | 353.0 ± 27 |
| CLB-PE | wt | A | >15000 | >4000 |
NA, nonamplified; A, amplified; g-o-f Δexon 4-11, gain-of-function deletion of exons in the extracellular domain of ALK; wt, wild-type.